In this article, Finnegan partner
Eric Raciti discusses the importance of proactive IP portfolios for medical-device companies facing increases in pricing pressure and competition due to healthcare reform. The authors argue that, with or without healthcare reform, the most competitive medical-device manufacturers will be those that develop innovative products, distinguish themselves from their competitors’ offerings, and maintain a competitive advantage through a strategic IP portfolio. Raciti and McAnulty explain that being smart about patent portfolio management can help companies reduce costs and also maximize value, and conclude that medical-device companies should be proactive with respect to their patent portfolio by prioritizing developments, focusing resources on high-value patents and applications, and evaluate the total-cycle costs associated with developing and maintaining a patent portfolio.